---
title: Medication Dosing and Timing for rTKA Anesthesia
version: 1.1
last-updated: 2025-12-08
---

# Medication Dosing and Timing for rTKA Anesthesia  
**Cohesive With Protocols 1–3 (OFIA + Blocks, OFIA Block-Free, Conventional Opioid Pathway)**  
**Educational Use Only – Not a Clinical Guideline**

---

## 1. Preoperative Medications (ERAS-Aligned)
- **Acetaminophen 1 g PO** — give 30–60 min pre-op; peak effect 45–60 min  
- **Celecoxib 400 mg PO** — give 1–2 hours pre-op (or meloxicam 15 mg PO if alternative needed)  
- **Dexamethasone 8–10 mg IV** — give after IV placement; onset 10–15 min  
- **Scopolamine 1.5 mg patch** — night before or ≥2 hours pre-op for high PONV risk  
- **Avoid gabapentinoids** (ASA/APSF 2024 — increased sedation, falls, respiratory depression)

---

## 2. Induction Agents  
**Doses below assume average adult; adjust for frailty, advanced age, cardiac disease, or renal impairment.**  
**Pathway-dependent differences shown in brackets.**

### Anxiolysis
- **Midazolam 1–2 mg IV pre-op** (holding area or prior to blocks)  
- **Midazolam 0.5–1 mg IV at induction** (lower range for elderly/OSA)

### Induction Sequence
- **Propofol 1.5–2 mg/kg IV** — onset 30–45 sec; duration 5–10 min  
- **Ketamine (pathway-dependent):**  
  - **0.3–0.5 mg/kg IV** — *with ACB + IPACK (Protocol 1)*  
  - **0.4–0.5 mg/kg IV** — *block-free OFIA (Protocol 2)*  
  - **0.2–0.3 mg/kg IV** — *conventional opioid pathway (Protocol 3)*  
- **Dexmedetomidine 0.5 mcg/kg IV over 10–20 min (optional)**  
  - Avoid loading dose in frail, bradycardia, or conduction disease.  
- **Magnesium sulfate 30–50 mg/kg IV over 15–20 min**  
  - **Avoid if CrCl <30 mL/min.**  
- **Lidocaine IV bolus 1–1.5 mg/kg (optional; Pathways 2–3 only)**  
  - Typically used in OFIA block-free pathway for systemic analgesia.  
- **Rocuronium 0.6–1.0 mg/kg IV** — onset 45–60 sec

---

## 3. Maintenance Infusions (with Pathway Notes)

### Primary Anesthetic
- **Sevoflurane 0.8–1.2 MAC**  
  OR  
- **Propofol TIVA 75–150 mcg/kg/min**

### Adjunct Infusions
- **Dexmedetomidine (pathway-dependent):**  
  - *Protocol 1 (blocks):* **0.2–0.7 mcg/kg/hr**  
  - *Protocol 2 (block-free):* **0.3–0.7 mcg/kg/hr**  
  - *Protocol 3 (opioid-based):* **0.2–0.4 mcg/kg/hr**  
- **Ketamine (pathway-dependent):**  
  - *Protocol 1:* **0.1–0.2 mg/kg/hr**  
  - *Protocol 2:* **0.15–0.25 mg/kg/hr**  
  - *Protocol 3:* **0.1–0.2 mg/kg/hr**  
- **Lidocaine infusion 1–2 mg/kg/hr** (optional; Pathways 2–3; max **300 mg total dose**)  

**Hemodynamics:**  
- Maintain **MAP ≥65 mmHg**  
  - Phenylephrine 50–100 mcg IV (HR >70)  
  - Ephedrine 5–10 mg IV (HR <60)

---

## 4. Emergence Timing  
- Stop **dexmedetomidine 10–15 min** before expected extubation  
- Stop **ketamine** at skin closure  
- Taper volatile agent or propofol infusion by ~50%  
- **Ondansetron 4 mg IV** before emergence  
- **Sugammadex 2 mg/kg** (TOF count ≥2) or **4 mg/kg** (deep block)

### Expected Wake-Up Time (Pathway-Dependent)
- **OFIA + Blocks (Protocol 1):** 5–10 minutes  
- **OFIA Block-Free (Protocol 2):** 5–10 minutes  
- **Conventional Opioid Pathway (Protocol 3):** 10–20 minutes (opioid-related somnolence)

---

## 5. PACU Rescue Analgesia
### First-Line (All OFIA Pathways)
- **Ketamine 0.1–0.15 mg/kg IV** q10–15 min  
  - Max 3 doses (~0.3–0.45 mg/kg total)

### Second-Line (Protocol 3 or rescue cases)
- **Hydromorphone 0.2 mg IV** q10–15 min PRN  
  - Reassess sedation, RR, SpO₂ after each dose

---

## 6. Regional Blocks (Pathway 1)
- **ACB:** 20–30 mL ropivacaine 0.2–0.25%  
- **IPACK:** 20 mL ropivacaine 0.2–0.25%  
- Maximum safe LA dose: **≈3 mg/kg** ropivacaine  
- **Lipid emulsion 20%** must be immediately available (LAST preparedness)  
- Follow ASRA 2024–2025 anticoagulation windows

---

## Notes
- All doses assume ~70 kg adult with normal organ function.  
- Adjust for frail elderly, OSA, renal/hepatic impairment, and cardiovascular disease.  
- Lidocaine infusions and higher ketamine doses apply mainly to **block-free or opioid-based pathways**, not the ACB/IPACK pathway.  
- Midazolam and sevoflurane remain fully compatible with OFIA principles.  
